SLU-PP-332 analysis

The SLU-PP-332 Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of SLU-PP-332 in oral dosage forms, lyophilised vials, and raw active pharmaceutical ingredient (API) powders.

The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule, as well as lyophilised vials, with results reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). SLU-PP-332 is not a peptide, and peptide purity is therefore not determined as part of this analysis.

About SLU-PP-332

SLU-PP-332 is a synthetic research compound that acts as an agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial metabolism, oxidative phosphorylation, and fatty-acid oxidation.

SLU-PP-332 has been investigated primarily in preclinical studies. In mouse models, activation of ERR signalling by SLU-PP-332 has been associated with increased oxidative skeletal muscle fibres, improved exercise endurance, increased energy expenditure, and enhanced fatty-acid oxidation.

Key Features

• Targeted identification and quantification of SLU-PP-332
• Suitable for pills, tablets, capsules, lyophilised vials, and raw API powders
• Analysis by HPLC
• Results for oral products reported in mg per tablet or capsule
• Results for lyophilised samples reported in mg per vial
• Alternative purity reporting in % (m/m)
• Minimum sample amount of three tablets or capsules
• Minimum sample amount of one whole unopened vial with lyophilisate
• Minimum sample amount of 200 mg for raw API powders
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: SLU-PP-332
• Testing method: HPLC
• Result format for oral products: mg per tablet or capsule
• Result format for lyophilised vials: mg per vial
• Result format for raw API powders: Purity in % (m/m)
• Minimum sample amount for oral products: Three tablets or capsules
• Minimum sample amount for lyophilised vials: One whole unopened vial with lyophilisate
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time: 7 business days

Important Notice

• SLU-PP-332 is not a peptide. Peptide purity is therefore not measured as part of this analysis.
• For lyophilised SLU-PP-332 samples, the standard testing procedure uses water (H₂O) as the solvent. However, SLU-PP-332 is poorly soluble in water, and insoluble material may therefore be filtered out before analysis. Only dissolved material can be analysed.
• DMSO can be selected as an alternative solvent because it dissolves SLU-PP-332 more effectively. However, samples dissolved in DMSO are not suitable for injection or human use. To use DMSO for the analysis, select the DMSO solvent option from the additional services.
• This analysis is specifically intended for SLU-PP-332. It does not automatically screen the sample for related compounds, contaminants, or undeclared substances.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Solvent: DMSO
• Fentanyl Screening
• Alternative Result Format: Purity in % (m/m)
• Batch Variance Testing
• CHNS Mass Report
• LCMS Screening for Peptide Contamination
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Additional Laboratory Report